Yazar "Kebapcilar, L." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    THE EFFECTS OF RALOXIFENE ON OSTEOCALCIN, AS A BONE TURNOVER MARKER IN ORCHIECTOMIZED RATS
    (EDITURA ACAD ROMANE, 2014) Saklamaz, A.; Uyulgan, B.; Sevin, G.; Kebapcilar, L.; Yilmaz, O.; Cimrin, D.; Kumanlioglu, K.
    Background. The aim of the present study was to measure the effects of raloxifene on bone metabolism and strength in orchiectomized male rats. Materials/Methods. Forty-three 4-month-old Wistar albino male rats were used and divided into 3 groups as orchiectomy (ORCX; n=23), sham (n=15), and control (n=5). Raloxifene (10 mg/kg/day) and methylcellulose (0.5 mL/day, as a vehicle treatment) treatments were initiated 2 months after ORCX for 2 months, then the rats were sacrificed. The left femur and fourth lumbar vertebrae (LV4) were measured to assess the effects of the orchiectomy and the raloxifene treatment and maintenance regimens. Bone strength was assessed using a compression test for the vertebrae and a three-point bending test for the femurs (N/mm). Results. Raloxifene increased femoral and vertebral bone strength in osteoporotic rats, but this increase was not statistically significant. Bone strength was found to be 267.44 +/- 18.03 in the femurs of the ORCX-raloxifene group and 246.32 +/- 49.37 in the femurs of the ORCX-C group (p>0.05). Vertebral bone strength was 147.78 +/- 09.51 in the ORCX-raloxifene group and 114.61 +/- 05.93 in ORCX-C group (p=0.488). Raloxifene also increased the femoral and vertebral bone density compared with the control group, but the change was not significant. While raloxifene significantly decreased the serum osteocalcin levels (p=0.007), it did not decrease the carboxyterminal cross-linking telopeptide of bone collagen (CTX) levels significantly (p=0.066). Conclusions. Raloxifene caused a statistically significant decrease in serum osteocalcin levels and a non-significant reduction in NTX levels in orchiectomized rats.
  • Küçük Resim Yok
    Öğe
    Evaluation the early effects of single high dose radioiodine therapy on lacrimal gland function
    (IJRR-IRANIAN JOURNAL RADIATION RES, 2014) Gedik, G. K.; Gedik, S.; Koktekir, B. E.; Kebapcilar, L.; Kara, P. O.
    Background: The therapeutic administration of I-131 for thyroid remnant ablation and for metastases comes up with some adverse effects. This study was conducted to investigate whether single high dose radioiodine therapy affects lacrimal gland functions or not. Materials and Methods: Seventy-eight eyes of 39 patients, who were diagnosed as differentiated thyroid carcinoma, were objectively tested with Schiermer's test and tear film break-uptime test; before and 1 and 6 months after high dose (>= 3700 MBq) I-131 therapy. Results: The median values of pre-treatment Schiermer's test were 10.00 mm and 9.60 mm for right and lefteyes, respectively. At the post-treatment first and sixth months, no significant change was observed in the median values of Schiermer's test in both eyes (p= 0.189 and p= 0.085, respectively, Friedman test). The median values of pre-treatment tear film break-uptime test were 9.15 sn and 9.20 sn for right and lefteyes, respectively. The median values of post-treatment tear film break-uptimes reduced at first and sixth months and the difference between the pre-treatment and post-treatment values were significant in both eyes (p=0.020 and p=0.022 for right and lefteyes, respectively, Friedman test). Conclusion: Impairment of goblet cell function occurs early after administration of single high dose I-131 application. However, reduction in tear secretion from lacrimal gland is not observed.